



Corporate Fact Sheet

Overview

Founded in Geneva, Switzerland, in 2003, Endosense is a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias. The company has pioneered the use of contact force measurement in catheter ablation with the development of its proprietary Touch+[®] sensor technology. Endosense's flagship product is the TactiCath[®], the first force-sensing ablation catheter to give physicians a real-time, objective measure of tip-to-tissue contact force during the catheter ablation procedure.

Market Focus

Endosense's therapeutic focus is the catheter ablation treatment of cardiac rhythm disorders. Atrial fibrillation (AF) is the most common cardiac rhythm disorder today, affecting more than six million people worldwide. Most AF patients are currently treated with ineffective and side effect-causing pharmaceutical drugs, with the primary alternative invasive ablation surgery. This sizeable patient population represents a multi-billion dollar market opportunity for Endosense and its groundbreaking catheter ablation technology.

Clinical Milestones

Endosense's TactiCath ablation catheter and supporting TactiSys[™] system have undergone extensive pre-clinical validation in the United States and Europe. The resulting pool of study data has created a solid foundation of evidence supporting the feasibility, safety and value of contact force sensing during catheter ablation.

Endosense's ongoing clinical research program currently includes:

- TOCCATA (TOuCh+ for CAThether Ablation), a multi-center, prospective outcomes study the results of which has demonstrated the safety, efficacy and value of the TactiCath in clinical practice (launched October 2008)
- EFFICAS, a series of studies intended series intended to demonstrate that the use of contact force control during cardiac ablation utilizing the TactiCath force-sensing catheter results in superior outcomes as compared to ablations performed without a force sensor (launched May 2010)

Commercial Milestones

The TactiCath and TactiSys were granted CE mark in October 2009 for the treatment of atrial fibrillation (AF) and supraventricular tachycardia (SVT). In April 2010, Endosense launched a second-generation product. The company's exclusive product distributor in Europe, Latin America, Canada, Africa and the Middle East is BIOTRONIK. The TactiCath is not currently available in the United States.

Financing

Endosense is backed by Edmond de Rothschild Investment Partners, Neomed, Gimv, VI Partners, Sectoral Asset Management, Ysios Capital Partners and Initiative Capital Romandie.

**Management
Team**

Eric Le Royer, President and Chief Executive Officer
Giovanni Leo, Co-founder and Chief Technology Officer
Andrea Buscaglia, Chief Financial Officer
Laurent Grandidier, Vice President, Sales and Marketing
Hendrik Lambert, Ph.D., Director, Clinical Affairs
Eric Giroud, Director, Quality Assurance and Regulatory Affairs

**Scientific
Advisors**

Warren Jackman, M.D., University of Oklahoma
Karl-Heinz Kuck, M.D., St. Georg Hospital, Hamburg
Hiroshi Nakagawa, M.D., Ph.D., University of Oklahoma
Andrea Natale, M.D., Texas Cardiac Arrhythmias Institute, Austin
Vivek Reddy, M.D., University of Miami Hospital
Nadir Saoudi, M.D., Ph.D., Princess Grace Hospital, Monaco
Dipen Shah, M.D., University Hospital of Geneva

**Contact
Information**

Endosense
Chemin du Grand-Puits 42
1217 Meyrin
Geneva, Switzerland

Phone: + 41 22 306 19 60
www.endosense.com

MEDIA CONTACT/U.S.:

Laura Nobles
Nobles Communications
310-795-0497
laura@noblescommunications.com

MEDIA CONTACT/EUROPE:

Danièle Castle
Genevensis
+41 22 779 06 20
info@genevensis.com

###